Didanosine

Generic Name
Didanosine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C10H12N4O3
CAS Number
69655-05-6
Unique Ingredient Identifier
K3GDH6OH08
Background

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse tra...

Indication

For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-03-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
740
Registration Number
NCT00001066
Locations
🇺🇸

HRS Palm Beach County Public Health Unit, West Palm Beach, Florida, United States

🇺🇸

Children's Hosp of Washington DC, Washington, District of Columbia, United States

🇺🇸

Howard Univ Hosp, Washington, District of Columbia, United States

and more 88 locations

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
55
Registration Number
NCT00007202
Locations
🇺🇸

AIDS Research Consortium of Atlanta, Inc. (ARCA) AIEDRP CRS, Atlanta, Georgia, United States

🇺🇸

Feinberg School of Medicine, HIV/ACTU AIEDRP CRS, Chicago, Illinois, United States

🇺🇸

Rush Univ. Med. Ctr., Dept. of Infectious Disease AIEDRP CRS, Chicago, Illinois, United States

and more 2 locations

Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-08-05
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
300
Registration Number
NCT00002035
Locations
🇺🇸

AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

🇺🇸

Albany Med College / AIDS Treatment Ctr, Albany, New York, United States

🇺🇸

Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States

and more 15 locations

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2014-04-17
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1710
Registration Number
NCT00000922
Locations
🇺🇸

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States

🇺🇸

Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States

🇺🇸

Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York, New York, United States

and more 14 locations

Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
280
Registration Number
NCT00000831
Locations
🇺🇸

USC CRS, Los Angeles, California, United States

🇺🇸

Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States

🇺🇸

Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

and more 37 locations

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
256
Registration Number
NCT00000838
Locations
🇺🇸

Stanford CRS, Palo Alto, California, United States

🇺🇸

Santa Clara Valley Med. Ctr., San Jose, California, United States

🇺🇸

San Mateo County AIDS Program, San Mateo, California, United States

and more 29 locations

A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC

Phase 1
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
30
Registration Number
NCT00000753
Locations
🇺🇸

USC CRS, Los Angeles, California, United States

🇺🇸

Univ. of Miami AIDS CRS, Miami, Florida, United States

🇺🇸

St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States

and more 3 locations

The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
200
Registration Number
NCT00001063
Locations
🇺🇸

Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States

🇺🇸

Bmc Actg Crs, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States

and more 30 locations

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-03-14
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
750
Registration Number
NCT00000671
Locations
🇺🇸

Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States

🇺🇸

Hemophilia Ctr of Western PA / Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States

and more 68 locations

A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

Phase 1
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
116
Registration Number
NCT00000656
Locations
🇺🇸

Univ of Washington, Seattle, Washington, United States

🇺🇸

Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto, California, United States

🇺🇸

Whitman - Walker Clinic, Washington, District of Columbia, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath